Lv51
1400 积分 2023-03-16 加入
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2小时前
待确认
Psoriasis
14天前
已完结
Atopic dermatitis
15天前
已完结
Atopic dermatitis
15天前
已完结
Improving IBD outcomes in the era of many treatment options
15天前
已完结
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
16天前
已完结
Pathophysiology of Inflammatory Bowel Diseases
16天前
已完结
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
17天前
已完结
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
17天前
已完结
皖公网安备34019202002308
